IN2014DN01791A - - Google Patents

Info

Publication number
IN2014DN01791A
IN2014DN01791A IN1791DEN2014A IN2014DN01791A IN 2014DN01791 A IN2014DN01791 A IN 2014DN01791A IN 1791DEN2014 A IN1791DEN2014 A IN 1791DEN2014A IN 2014DN01791 A IN2014DN01791 A IN 2014DN01791A
Authority
IN
India
Prior art keywords
prevention
treatment
invention concerns
receptor antagonists
ampa receptor
Prior art date
Application number
Other languages
English (en)
Inventor
Klaus Kucher
Donald Johns
George Imbert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN01791A publication Critical patent/IN2014DN01791A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1791DEN2014 2011-09-07 2011-09-07 IN2014DN01791A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
IN2014DN01791A true IN2014DN01791A (es) 2015-05-15

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1791DEN2014 IN2014DN01791A (es) 2011-09-07 2011-09-07

Country Status (10)

Country Link
EP (1) EP2753331A1 (es)
JP (1) JP2014525474A (es)
KR (1) KR20140071405A (es)
CN (1) CN103889427A (es)
AU (1) AU2011376333A1 (es)
BR (1) BR112014005210A2 (es)
CA (1) CA2846503A1 (es)
IN (1) IN2014DN01791A (es)
MX (1) MX2014002693A (es)
WO (1) WO2013036224A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
CA3008170A1 (en) 2015-12-30 2017-07-06 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
EP1677790A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
JP2007509934A (ja) 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキン類ｉｉｉ
WO2005044266A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
CA2555402A1 (en) 2004-02-12 2005-09-01 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
EP2496220B1 (en) * 2009-11-03 2019-10-16 Lupin Limited Modified release formulation of lacosamide

Also Published As

Publication number Publication date
MX2014002693A (es) 2014-06-04
EP2753331A1 (en) 2014-07-16
AU2011376333A1 (en) 2014-03-13
WO2013036224A1 (en) 2013-03-14
JP2014525474A (ja) 2014-09-29
CN103889427A (zh) 2014-06-25
KR20140071405A (ko) 2014-06-11
BR112014005210A2 (pt) 2017-03-21
CA2846503A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
GB201017345D0 (en) Receptor antagonists
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX360710B (es) Antagonistas de il17c para el tratamiento de trastornos inflamatorios.
PH12018500282A1 (en) Cgrp receptor antagonists
HK1206721A1 (en) 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23--
FR2979931B1 (fr) Potelet de garde-corps ou d'echafaudage equipe d'un bloqueur perfectionne
HK1201729A1 (zh) -抑制劑在治療中樞神經系統繼發性水腫中的應用
HK1204325A1 (en) Phragamalin limonoids for the treatment of sexual dysfunction phragmalin
AP2012006630A0 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
IN2014DN00254A (es)
HUE045270T2 (hu) FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
GB2499487B (en) Floating-point of the invention
IN2014DN01791A (es)
GB201012359D0 (en) Invention 6.5.10
SG11202111525XA (en) Stable targeted integration
FR2996871B1 (fr) Dispositif de correction de la courbure d'une dalle de plancher
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
IN2012DN00235A (es)
MX2015001134A (es) Compuestos terapeuticos.
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201009094D0 (en) Compounds for the treatment of closridium difficile-associated disease